Akums Drugs and Pharmaceuticals Limited has released its financial results for the quarter and year ended March 31, 2026. The Board of Directors has recommended a final dividend of ₹1.00 and a special dividend of ₹2.00 per equity share, totaling ₹3.00 per share. The company reported a standalone profit of ₹1,116.40 million for the full financial year and a consolidated profit of ₹2,563.97 million, reflecting robust operational activity.
Financial Performance Overview
For the financial year ended March 31, 2026, Akums reported strong consolidated performance, with revenue from operations reaching ₹43,590.17 million, compared to ₹41,181.58 million in the previous year. The consolidated net profit for the year stood at ₹2,563.97 million. On a standalone basis, the company achieved an annual revenue of ₹13,487.36 million with a net profit of ₹1,116.40 million.
Dividend Recommendations
The Board of Directors has proposed a dividend for the financial year 2026, comprising a final dividend of ₹1.00 per equity share (50%) and a special dividend of ₹2.00 per equity share (100%). The company has fixed July 3, 2026, as the Record Date to determine shareholder eligibility for these payments, which are subject to approval at the upcoming 22nd Annual General Meeting.
Leadership and Operational Updates
The company announced strategic leadership changes within its senior management effective May 14, 2026, appointing Mr. V Jagannathan as the new President – HR, while Mr. Arvind Srivastava has ceased his role as President – HR. Furthermore, the company has appointed Mahajan & Aibara LLP as internal auditors and re-appointed M/s. Balwinder & Associates as cost auditors for the upcoming fiscal year.
Annual General Meeting
The company has scheduled its 22nd Annual General Meeting to be held via video conferencing on July 10, 2026, at 11:00 AM IST. Shareholders will deliberate on the annual report and the recommended dividend payouts during this meeting.
Source: BSE
